Sign In
Buy NXTC
$4.15
-0.89 (-17.59%)
At Close: Jul 31, 2026
The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
03:09pm, Friday, 15'th Nov 2019
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89
NextCure Announces Pricing of Public Offering of Common Stock
03:10am, Friday, 15'th Nov 2019
BELTSVILLE, Md., Nov. 14, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.
NextCure Announces Proposed Public Offering of Common Stock
09:18pm, Tuesday, 12'th Nov 2019
NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today
